Immunocore Holdings plc American Depositary Shares
IMCR
IMCR: Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
moreShow IMCR Financials
Recent trades of IMCR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IMCR's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: T cell receptors Aug. 08, 2023
-
Patent Title: T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex May. 02, 2023
-
Patent Title: T cell receptors Nov. 22, 2022
-
Patent Title: Engineered immune-mobilizing t-cell receptors with enhanced affinity for hiv-1 gag Sep. 13, 2022
-
Patent Title: T cell receptors Aug. 30, 2022
-
Patent Title: Tcr libraries Oct. 05, 2021
-
Patent Title: Tcr libraries Sep. 21, 2021
-
Patent Title: Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex May. 25, 2021
-
Patent Title: Peptides derived from transient receptor potential cation channel subfamily m member 1 (trpm1), complexes comprising such peptides bound to mhc molecules Apr. 20, 2021
-
Patent Title: Peptides derived from transient receptor potential cation channel subfamily m member 1 (trpm1), complexes comprising such peptides bound to mhc molecules Mar. 16, 2021
-
Patent Title: Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex Mar. 02, 2021
-
Patent Title: Peptides derived from lengsin (lgsn), complexes comprising such peptides bound to mhc molecules Dec. 01, 2020
-
Patent Title: Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc molecules Nov. 17, 2020
-
Patent Title: Peptides derived from actin-like protein 8 (actl8) Oct. 06, 2020
-
Patent Title: Bifunctional polypeptides Mar. 03, 2020
-
Patent Title: Bifunctional polypeptides Dec. 31, 2019
-
Patent Title: Bifunctional polypeptides Sep. 24, 2019
-
Patent Title: Bifunctional polypeptides Nov. 20, 2018
-
Patent Title: High affinity hiv t cell receptors Feb. 09, 2016
-
Patent Title: Cells expressing modified t cell receptor Aug. 25, 2015
-
Patent Title: Nucleic acid molecules encoding non-naturally occurring t cell receptors and cells thereof Jun. 30, 2015
-
Patent Title: T cell receptor display Jun. 03, 2014
-
Patent Title: Non-naturally occurring t cell receptors Aug. 27, 2013
-
Patent Title: High affinity hiv t cell receptors Feb. 19, 2013
-
Patent Title: High affinity ny-eso t cell receptors Feb. 05, 2013
-
Patent Title: Cells expressing a modified t cell receptor Jan. 29, 2013
-
Patent Title: T cell receptor mutants Oct. 09, 2012
-
Patent Title: High affinity melan-a t cell receptors Jul. 10, 2012
-
Patent Title: High affinity ny-eso t cell receptor Mar. 27, 2012
-
Patent Title: T cell receptors which specifically bind to vygfvracl-hla-a24 Sep. 13, 2011
-
Patent Title: High affinity ny-eso t cell receptors Aug. 30, 2011
-
Patent Title: Soluble t cell receptors Jul. 27, 2010
-
Patent Title: Modified soluble t cell receptor Feb. 23, 2010
Federal grants, loans, and purchases
Followers on IMCR's company Twitter account
Number of mentions of IMCR in WallStreetBets Daily Discussion
Recent insights relating to IMCR
Recent picks made for IMCR stock on CNBC
ETFs with the largest estimated holdings in IMCR
Flights by private jets registered to IMCR